Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fangzhou Inc. (6086.HK)
Guangzhou, CN
Headquartered in Guangzhou, China, Fangzhou Inc. delivers comprehensive online chronic disease management services throughout the nation. The company leverages its dedicated digital platform to assist individuals grappling with long-term health issues like hypertension, cardiovascular, and respiratory conditions. Its mobile application facilitates a suite of "H2H" services, comprising virtual medical consultations, e-prescribing, and prescription renewal options. Furthermore, Fangzhou provides healthcare products through an online retail pharmacy and manages its own network of hospitals and brick-and-mortar pharmacies. The company was established in 2015.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.41% | +7.06% | -28.91% | -59.73% | -71.02% | -59.56% | -77.59% | -79.91% | -79.91% | -79.91% | -79.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+30.2% ★ Q4'25: +87.3% (vs Q4'23)
-
EPS growth Drug Manufacturers - General: +18.2%+101.0% ★ Q4'25: +99.3% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+1.1% Q4'25: +1.7% (vs Q4'23)
-
EBIT margin Drug Manufacturers - General: +19.4%+0.4% Q4'25: -0.1% (vs Q4'23)
-
ROIC Drug Manufacturers - General: +10.2%— Q4'25: +2.8% (vs Q4'23)
-
Share dilution Drug Manufacturers - General: +0.0%+37.9% Q4'25: +81.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×2.23× ★ Q4'25: 17.62× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
3.53B
est: 3.23B (+9.1%)
|
4.80B
4.74B – 4.87B
+48.5% YoY
|
6.42B
6.24B – 6.61B
+33.8% YoY
|
7.94B
7.76B – 8.11B
+23.6% YoY
|
| EBITDA |
16.05M
est: -337.35M (+104.8%)
|
-501.04M
-507.88M – -494.20M
-48.5% YoY
|
-670.42M
-689.41M – -651.43M
-33.8% YoY
|
-828.58M
-846.85M – -810.31M
-23.6% YoY
|
| EBIT |
12.52M
est: -346.59M (+103.6%)
|
-514.76M
-521.79M – -507.74M
-48.5% YoY
|
-688.78M
-708.29M – -669.28M
-33.8% YoY
|
-851.28M
-870.05M – -832.51M
-23.6% YoY
|
| Net Income |
11.83M
est: 13.45M (-12.0%)
|
48.01M
46.63M – 49.38M
+256.9% YoY
|
107.34M
104.27M – 110.42M
+123.6% YoY
|
199.72M
194.00M – 205.44M
+86.1% YoY
|
| SGA |
550.23M
est: 771.26M (-28.7%)
|
1.15B
1.13B – 1.16B
+48.5% YoY
|
1.53B
1.49B – 1.58B
+33.8% YoY
|
1.89B
1.85B – 1.94B
+23.6% YoY
|
| EPS |
0.01
est: 0.01 (-11.0%)
|
0.04
0.03 – 0.04
+256.9% YoY
|
0.08
0.08 – 0.08
+123.6% YoY
|
0.15
0.14 – 0.15
+86.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 1.8K | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Zhou | Chief Strategy Officer & Executive Director | 4M | male |
| Yuming Zou | Executive Director, Chief Financial Officer & Joint Company Secretary | 2M | male |
| Haijiao Wang | CEO & Executive Director | — | male |
| Sau Mei Ng ACIS FCIS | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6086.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
